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Abstract
In 1961, the first combined oral contraceptive pill was 
introduced in Europe.  This pill contained ethinylestradiol 
(0.05mg) and northisterone (4mg).  Nowadays, monophasic pill 
preparations contain a low dose (20–35 μg) of ethinylestradiol 
in combination with a progestogen.  Progestogens include 
norethisterone and levonorgestrel (second generation); 
desogestrel and gestodene (third generation); and the 
newest progestogen, drospirenone (fourth generation). 
Risks of the combined oral contraceptive pill include venous 
thromboembolism and stroke.  Benefits, such as protection 
from ovarian and endometrial cancer, apart from contraception, 
outweigh the risks if contraindications are observed, and low 
dose formulations used.
In 1931, Ludwig Haberlandt, Professor of Physiology 
in Innsbruck, Austria wrote: ‘of all the methods available, 
hormonal sterilisation, based on a biological principle,  if it 
can be applied unobjectively in the human, is the ideal method 
for practical medicine and its future task of birth control.’ His 
experiments involved transplanting ovaries from pregnant 
rabbits under the skin of fertile adult does, and he found that 
they become infertile. 
The three most well-known persons who are considered the 
pioneers in the development of the oral contraceptive pill are 
Margaret Sanger, Katherine Dexter McCormick and Gregory 
Goodwin Pincus. They had met in 1951 to initiate the project 
that resulted in marketing the first oral contraceptive. Margaret 
Sanger was a nurse specialising in obstetric care, who introduced 
the term ‘birth control’ in 1914 in America through a monthly 
magazine entitled ‘The Woman Rebel’, which she edited. In 
1950, Katherine Dexter McCormick, a philanthropist, sent a 
letter to Sanger indicating her interest in supporting ‘further 
contraceptive research.’ Both women had long been aware of the 
pressing social and population problems caused by the lack of 
adequate birth control. The political and social climate was such 
that it was strictly unlawful to advise, prescribe or instruct on the 
use of contraceptives. Sanger referred McCormick to Dr Gregory 
Goodwin Pincus, a biological scientist expert in endocrinology 
and mammalian reproduction at the Worcester Foundation for 
Experimental Biology. In 1951, Pincus accepted to start working 
on the development of a physiological contraceptive for safe 
mass use, and his research was funded by McCormick. 
The first experiments started on 21st April 1951, and in 1960 
the first oral contraceptive pill was patented as Enovid-10, 
containing 0.15mg of mestranol as oestrogen component and 10 
mg norethinodrel. Clinical trials were carried out in Puerto Rico 
and Haiti. Pharmaceutical companies became eager to enter 
the fast-growing oral contraceptive market.  In 1961, Schering 
AG of Berlin, introduced the Pill in Europe. This was called 
Anovlar, which contained the progestogen, northisterone (4mg), 
but the oestrogen component was changed from mestranol to 
ethinylestradiol (0.05mg). Ortho Pharmaceutical Co. received 
the approval of the US Food and Drug Administration (FDA) to 
market its Pill Ortho-Novum, which contained the progestogen 
norethindrone. Pill use rose from half a million women in 
the USA in 1961 to about 4 million in 1965, and is now used 
worldwide. The Pill continues to be the most studied medication 
to ever come to the market, with new data emerging on its health 
benefits and risks.1 * corresponding author
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 Progestogenic Glucocorticoid Androgenic Antiandrogenic Antimineralocorticoid
Progesterone + - - (+) +
Drospirenone + - - + +
Levonorgestrel + - (+) - -
Gestodene + - (+) - (+)
Norgestimate + - (+) - -
Desogestrel + - (+) - -
Dienogest + - - + -
Cyproterone acetate + (+) - + -
- no effect   (+) mild effect   + strong effect
In Malta, the hormonal oral contraceptives were introduced 
in the mid-1960s, but were being advertised as menstrual cycle 
regulators.  In spite of their availability on the local market in the 
70s, only 2% of the female population interviewed were using 
hormonal contraception. Twenty years later, by 1993, the usage 
rate had increased to 15.8%.2 
Pharmacology
The term ‘combined oral contraception’ (COC) is used 
to describe monophasic preparations containing a low dose 
(20–35 μg) of ethinylestradiol in combination with a progestogen. 
Progestogens include norethisterone and levonorgestrel (second 
generation); desogestrel and gestodene (third generation); and 
the newest progestogen, drospirenone (fourth generation). 
The progestogenic component of a COC usually determines 
the overall metabolic and clinical effects, and consequently, 
distinguishes between different brands and influences choice 
(Table 1).  Generally a preparation with the lowest oestrogen 
and progestogen content which gives good cycle control and 
minimal side-effects in the individual woman is chosen.
The oral contraceptive pills available in Malta include 
Mercilon®, Meliane® Cilest®, Gynera® and Minesse®.  Mercilon® 
(Organon) contains 150 μg desogestrel and 20 μg ethinylestradiol. 
Cilest® (Janssen-Cilag) contains 250 μg of norgestimate and 
35 μg ethinylestradiol. Gynera® (Schering) contains 75 μg 
gestodene and 30 μg ethinylestradiol.  Minesse® (Wyeth-Ayerst) 
is different from the other combined oral contraceptive pills 
because it is a 24 day regimen, with each pill containing 60 μg 
gestodene and only 15 μg of  ethinylestradiol.
Contraceptive technology has rapidly progressed as further 
insights into basic mechanisms of physiology and pharmacology 
have been gained. The introduction of drospirenone as a progestin 
in COCs was one recent development. Unlike other progestins, 
drospirenone is a derivative of spirolactone and has anti-
mineralocorticoid activity. The antimineralocorticoid activity of 
drospirenone reduces the oestrogen-induced water retention, 
via the renin-angiotensin-aldosterone-system.  In addition, 
drospirenone exhibits anti-androgenic activity by blocking 
androgen receptors. Yasmin® (Schering) is a monophasic COC 
formulated as tablets containing 30μg ethinylestradiol and 3mg 
drospirenone, taken once daily for 21 days followed by a 7-day 
hormone-free interval. A new low-dose formulation based on 
drospirenone has been developed and is marketed under the 
brand name Yasminelle®. Yasminelle® is formulated with a lower 
oestrogen dose than Yasmin® (20μg vs 30μg ethinylestradiol), 
but with the same drospirenone dose (3mg). In Yasminelle®, 
ethinylestradiol is contained in a betadex (beta-cyclodextrin) 
clathrate-one molecule of ethinylestradiol within two molecules 
of betadex. This formulation was done in order to improve 
stability at low hormone concentrations and prolong shelf-life. 
The calculated dissociation half-life of this complex molecule 
is 26 minutes. Therefore the pharmacokinetics and relative 
bioavailabilty of ethinylestradiol are unaffected. A multicentre 
trial showed that Yasminelle® is an effective contraceptive 
with a Pearl Index of 0.23 (upper limit of 97.5% CI 0.84), 
with improved emotional and physical well-being, stable body 
weight, reduction of acne and good overall tolerance.3 The main 
disadvantage over the higher dose ethinylestradiol formulations 
is that of an increased rate of intracycle bleeding (20.8% in 
the first cycle and up to 11.3% in subsequent cycles). A study 
comparing Yasminelle® with ethinylestradiol 20 μg/desogestrel 
150μg (Mercilon®) showed a comparable cycle control, safety, 
and efficacy profile.4
Risks of the Combined Oral Contraceptive Pill
Venous thromboembolism
By 1970, the risk of venous thromboembolism (VTE) was 
known to be associated with the dose of oestrogen, which 
was consequently reduced. A WHO study in 1995 concluded 
that COC users had a relative risk of 3.2-4.1 of venous 
thromboembolism compared with non-users.5 Therefore relative 
risk of venous thromboembolism is increased with combined 
oral contraceptive use. Nevertheless, the rarity of venous 
thromboembolism in women of reproductive age means that 
the absolute risk remains small.6
The risk appeared within 4 months of starting the COC and 
disappeared within 3 months of stopping, and decreases with 
duration of use, however remaining higher than in non-users. 
The risk was higher with COCs containing third-generation 
progestogens than with those containing second-generation 
Table 1: Pharmacological profiles of various progestins 
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progestogens. The relative risks were 2.6, 5.3 and 5.7 for 
COCs containing levonogestrel, desogestrel and gestodene, 
respectively, all of which are within the recognised range.6 
According to the Royal College of Obstetricians and 
Gynaecologists, a levonorgestrel- or norethisterone-containing 
combined oral contraceptive should be advised as a pill of first 
choice. However, after counselling, a woman may choose a 
desogestrel- or gestodene containing combined pill.6
Describing risk in relative terms may sound more alarming 
than in absolute terms.  The risk of VTE in non-users is low (5 per 
100,000 woman years).This increases to 15 per 100,000 woman 
years with COCs containing levonorgestrel or norethisterone 
and to 25 per 100,000 woman years with COCs containing 
desogestrel or gestodene.6 Thus, venous thromboembolism is 
uncommon in women of reproductive age and despite a five-fold 
increase in risk for women using gestodene- or desogestrel-
containing COCs, the absolute risk remains small (Table 2).6
Myocardial infarction
COCs are contraindicated in smokers over the age of 35, due 
to increased risk. A recent study in the UK concluded that there 
was no association between COCs and myocardial infarction.7 
A European multicentre study has also shown that there is a 
reduced risk associated with third-generation COCs.8
Stroke
COCs with a higher dose of ethinylestradiol increase the 
risk of stroke. Recent studies concluded that the relative risk 
of haemorrhagic stroke is 1.0-1.73, and for ischaemic stroke is 
2.85. No difference was found between pills containing different 
progestogens.9, 10
Hypertension
COCs have been shown to cause a ‘statistically significant 
but clinically unimportant’ rise of 1.0mmHg in diastolic 
pressure.11
Breast cancer
In 1996, a metanalysis of 54 studies, ranging from 1976 
to 1992, reached two main conclusions. Firstly, during COC 
use and for 10 years afterwards, the relative risk of developing 
breast cancer is 1.24 in users and 1.07 5-9 years after stopping. 
Breast cancers in COC users tended to be less advanced than 
in non-users. Secondly, there is no excess risk of breast cancer 
10 or more years after stopping COC use. The dose and type of 
hormone had little effect.12
One should note that in the above meta-analysis, many 
subjects had been taking the pill in the high-dose era. There 
is evidence that low-dose COCs stimulate the breast less, and 
therefore further studies are required, as the effects of currently 
used COCs may be less than those in this analysis.12
Cervical cancer
After differences in sexual activity and the use of barrier 
methods (which have a protective effect) have been accounted 
for, there appears to be no increase in the risk of cervical 
squamous carcinoma among women who take COCs.13 However, 
COC usage increases the risk of cervical adenocarcinoma, with 
a relative risk of 4.4 in women using the pill for more than 12 
years.14 
Liver disease
COC use increases the risk of hepatocellular adenoma and 
carcinoma. There is relative risk of 1.6 of symptomatic gallstones 
for current COC use, and use for more than 15 years.15
 Relative Risk Absolute Risk per 
  100,000 woman-years
Not using COC   5 in 100,000
COC containing levonorgestrel or norethisterone 3-fold increase 15 in 100,000
COC containing gestodene or desogestrel 5-fold increase 25 in 100,000
Pregnancy 12-fold increase 60 in 100,000
Table 2: Risk table for combined oral contraceptive (COC) users and risk of venous thromboembolism 
Ectopic Pregnancy  90%
Cancer  
Ovary 40%
Endometrium 40%
Benign Breast Disease 40%
Ovarian Cysts
Solid Tumours 20%
Follicular Cysts 49%
Luteal Cysts 78%
Fibroids (after 5 years’ COC use) 15%
Pelvic Inflammatory Disease 50%
Menorrhagia 50%
Iron Deficiency Anaemia 50%
Dysmenorrhoea 40%
Table 3: Benefits of the Pill: Risk Reduction in %17 
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Bowel disease
Recent use of COCs increased the risk of both ulcerative 
colitis (relative risk of 2.0) and Crohn’s disease (relative risk 
2.6). Women who had used COCs for more than 6 years had an 
increased risk of Crohn’s disease (relative risk of 5.1), but the 
risk of ulcerative colitis was not associated with duration of use 
and seemed to be restricted to high-oestrogen COCs.16
Benefits of the pill: risk reduction in %16
Use of the COC pill has been shown to decrease the risk of a 
number of pathological conditions in women. The risk reduction 
for these is shown expressed as a percentage (Table 2).
Conclusion
Over the past 45 years, there have been great developments 
in the field of oral contraception.  Nowadays, the health benefits 
of the pill greatly outweigh the risks, provided contraindications 
are observed, and low dose formulations are used.  
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